SUPPLEMENTAL WORK - SARS-COV-2 PRECLINICAL WORK

补充工作 - SARS-COV-2 临床前工作

• 批准号: 10259992
• 负责人: LAURIE SOWER
• 金额: $ 150.02万
• 依托单位: CHRYSALIS BIOTHERAPEUTICS, INC.
• 依托单位国家: 美国
• 财政年份: 2020
• 资助国家: 美国
• 起止时间: 2020-06-05 至 2021-05-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/10259992
• 关键词: 2019-nCoV; Acute Lung Injury; Address; Adult Respiratory Distress Syndrome; Adverse effects; Biological Assay; COVID-19; Clinical; Clinical Trials; Documentation; Dose; Endothelium; Equipment and supply inventories; Human; Infection; Inflammation; Normal tissue morphology; Patients; Pharmaceutical Preparations; Phase I Clinical Trials; Phase II Clinical Trials; SARS coronavirus; Safety; Schedule; Work; human subject; preclinical study; prevent; regenerative; tissue regeneration

Chrysalis proposes to repurpose their regenerative drug, TP508, to treat COVID-19, due to its ability to reduce effects of acute lung injury, prevent normal tissue damage and reduce inflammation. TP508 has an existing efficacy profile in tissue regeneration clinical trials, an extensive safety profile (600 human subjects with no adverse effects), and is GMP manufactured with sufficient inventory to enter COVID-19 clinical trials. The drug addresses underlying causes of ARDS, including loss of endothelial function.

Chrysalis建议重新利用其再生药物TP508，以治疗Covid-19，因为它能够减少急性肺损伤的影响，防止正常组织损伤并减少炎症。 TP508在组织再生临床试验中具有现有的功效概况，具有广泛的安全性（600名没有不良反应的人类受试者），并且具有GMP，并具有足够的库存，可以进入Covid-19-19。该药物解决了ARD的根本原因，包括丧失内皮功能。